Moderate to Severe Atopic Dermatitis: When to Treat Versus When to Refer – A Wheel of Knowledge Challenge!

1.25 CME
1.25 AAFP
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Moderate to Severe Atopic Dermatitis: When to Treat Versus When to Refer – A Wheel of Knowledge! Challenge

Overview


Provider Statement

This continuing education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


Activity Description

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease regularly encountered in primary care. Management of mild AD can be straightforward, but treatment for moderate-to-severe disease is challenging due to high disease burden and significant effects on quality of life, psychosocial function, and academic/occupational performance. The therapeutic landscape for moderate-to-severe AD has evolved and grown significantly in recent years—presenting new opportunities and challenges for clinicians. Ongoing education is needed to provide guidance on appropriate use of newer therapies, indications for specialty referral, and best practices for multidisciplinary management. In this educational activity, faculty will discuss pathophysiology and disease burden, the latest data supporting targeted systemic therapy, and strategies for utilizing multidisciplinary and interprofessional care for patients with moderate-to-severe AD. This program will include Wheel of Knowledge Challenge!, a unique, educational gaming platform.


Target Audience

This education is intended for US-based learners that include family medicine physicians, dermatologists, nurse practitioners, physician associates, and other healthcare professionals involved in the management of patients with AD.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the burden and pathophysiology associated with moderate to severe AD.
  • Assess the latest clinical data, including mechanism of action and real-world studies, of targeted systemic therapies for the treatment of moderate to severe AD.
  • Evaluate when multidisciplinary/interprofessional care should be utilized for patients with moderate to severe AD.

Activity Chair

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Jefferson Abington Health
Abington, PA


Faculty

Sarah L. Chamlin, MD
Division of Dermatology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Medical Director, Vascular Lesion Clinic
Northwestern University Feinberg School of Medicine
Chicago, IL

Robert Sidbury, MD, MPH, FAAD
Professor, Department of Pediatrics
Division Head, Dermatology
Seattle Children’s Hospital
University of Washington School of Medicine
Seattle, WA


Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

ACCME Jointly accredited In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Moderate to Severe Atopic Dermatitis: When to Treat Versus When to Refer – A Wheel of Knowledge! Challenge and deemed it acceptable for up to 1.25 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 11/29/2023 to 11/28/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Associates (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME. PAs may receive a maximum of 1.25 credit hours for completing this program.

This enduring material is approved for 1 year from the date of original release, November 29, 2023, to November 28, 2024.


How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or Self-Study AAFP Prescribed credits certificate.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Sarah L. Chamlin, MD
Speaker Contracted by Ineligible Company: Regeneron, Sanofi
External Data Monitoring Committee: Merck

John J. Russell, MD, FAAFP
Advisor: Bayer, GSK, Pfizer, Sanofi

Robert Sidbury, MD, MPH, FAAD
Consultant: Arcutis, Dermavant, LEO Pharma, Lilly
Independent Research Contractor: Galderma, Pfizer, Regeneron, UCB

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CE Questions?

Contact us at cme@vindicoCME.com